SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled "S8 Immunotoxicity Studies for Human Pharmaceuticals." Ťhe draft guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The draft guidance describes a weightof-evidence approach to determining whether additional immunotoxicity testing for nonbiological pharmaceuticals is appropriate when the findings from standard toxicity studies indicate signs of immunotoxicity. The draft guidance is intended to provide recommendations on nonclinical testing to identify compounds that have the potential to be immunosuppressive and guidance on a weight-of-evidence decision making approach for immunotoxicity testing. **DATES:** Submit written or electronic comments on the draft guidance by April 11, 2005. General comments on agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or the Office of Communication, Training and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448. The guidance may also be obtained by mail by calling the CBER Voice Information System at 1-800-835-4709 or 301-827-1800. Send one self-addressed adhesive label to assist the office in processing your requests. Submit written comments on the draft guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http:// www.fda.gov/dockets/ecomments. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT:

Regarding the guidance: Kenneth L. Hastings, Center for Drug Evaluation and Research (HFD–024), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5922.

Regarding the ICH: Michelle Limoli, Office of International Programs (HFG–1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 4480.

SUPPLEMENTARY INFORMATION:

I. Background

ICH was organized to provide an opportunity for tripartite harmonization initiatives to be developed with input from both regulatory and industry representatives. FDA also seeks input from consumer representatives and others. ICH is concerned with harmonization of technical requirements for the registration of pharmaceutical products among three regions: The European Union, Japan, and the United States. The six ICH sponsors are the European Commission, the European Federation of Pharmaceutical Industries Associations, the Japanese Ministry of Health, Labour, and Welfare, the Japanese Pharmaceutical Manufacturers Association, CDER and CBER (FDA). and the Pharmaceutical Research and Manufacturers of America. The ICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation of Pharmaceutical Manufacturers Associations.

The ICH Steering Committee includes representatives from each of the ICH sponsors and the IFPMA, as well as observers from the World Health Organization (WHO), Health Canada, and the European Free Trade Area.

In November 2004, the ICH Steering Committee agreed that a draft guidance entitled "S8 Immunotoxicity Studies for Human Pharmaceuticals" should be made available for public comment. The draft guidance is the product of the Safety Expert Working Group of the ICH. Comments about this draft guidance will be considered by FDA and the Safety Expert Working Group.

The draft guidance describes a weight-of-evidence approach to determining whether additional immunotoxicity testing for nonbiological pharmaceuticals is appropriate when the findings from standard toxicity studies indicate signs of immunotoxicity. The draft guidance provides the following: (1) Recommendations on nonclinical testing approaches to identify compounds which have the potential to be immunosuppressive and (2) guidance on a weight-of-evidence decision making approach for immunotoxicity testing. The primary data are from routine nonclinical toxicology studies conducted during drug development. Additional causes for concern that can affect the decision for additional

immunotoxicity testing include the pharmacology of the drug, intended patient population, known drug class effects, and retention of the drug in cells of the immune system.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). This draft guidance, when finalized, will represent the agency's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments on the draft guidance. Two copies of mailed comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Persons with access to the Internet may obtain the document at http://www.fda.gov/ohrms/dockets/default.htm, http://www.fda.gov/cder/guidance/index.htm, or http://www.fda.gov/cber/publications.htm.

Dated: February 1, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy. [FR Doc. 05–2418 Filed 2–7–05; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Program Exclusions: January 2005

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of January 2005, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under

the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, *e.g.*, a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and nonprocurement programs and activities.

Subject name	Address	Effective date		
PROGRAM-RELATED CONVICTIONS				
ABENDROTH, MICHAEL	FLORENCE, CO	2/20/200		
AKHIGBE, SAMUEL		2/20/200		
ALLCUTT, JOSEPH	ALEXANDRIA, LA	2/20/200		
ALVARINO, MAGDA	MIAMI, FL	2/20/200		
ARMSTRONG, JONI	FORT SMITH, AR	2/20/200		
BALL, DARCY		2/20/200		
BAQUERIZO, MARIA	MIAMI, FL	2/20/200		
BROOKS, GLORIA	RENTON, WA	2/20/200		
BROWN, HEATHER		2/20/200		
CHAMBERS, DEANA		2/20/200		
DADYAN, GEGAM	LONG BEACH, CA	2/20/200		
DE LA VEGA, HAYDEE	MIAMI, FL	2/20/200		
DENNIE, TONY	MCDONOUGH, GA	2/20/200		
DUNN, FREDERIC	GULFPORT, MS	2/20/200		
THERTON, JERAMEY	LEXINGTON, KY	2/20/200		
FALCON, CORINA	DOWNEY, CA	2/20/200		
FIELDS, JEFFREY	SAN ANTONIO, TX	2/20/200		
FLORES, JUAN	LOS ANGELES, CA	2/20/200		
GOODMAN, GARY		2/20/200		
IARRIS, LINDA		2/20/200		
HICKS, CAROLYN		2/20/200		
IAMEŚ, ALMA	i i	2/20/200		
IIMENÉZ, ANAY		2/20/200		
IOHNSON, ROSEMARY		2/20/200		
EAHEY, ROBERT		2/20/200		
ITTLETON, DARLENE	The state of the s	2/20/200		
OPEZ, LIZZETTE	· · · · · · · · · · · · · · · · · · ·	2/20/200		
MCKINNEY, MICHELLE		2/20/200		
MURPHY, MONICA	i i	2/20/200		
PARRISH, VIVIAN		2/20/200		
PEKERMAN, KONSTANTYN		2/20/200		
PENA, OVIDA		2/20/200		
PORBEN, MIRIAM		2/20/200		
PRIME CARE SERVICES, INC		2/20/200		
QUEVEDO, IDANYS	HIALEAH, FL	2/20/200		
RODRIGUEZ, ALEXIS	MIAMI, FL	2/20/200		
RODRIGUEZ, ALFONSO	MIAMI, FL	2/20/200		
SARMIENTO, DAISY	MIAMI, FL	2/20/200		
SCHMITT, DERIL		2/20/200		
ST JOHN, SAMUEL	PHENIX, VA	2/20/200		
EJEDA, MARIA	MIAMI, FL	2/20/200		
TYLER, JOLIE		2/20/200		
/ELAZCO, REBECA	MIAMI, FL	2/20/200		
/IDA, ALAIN		2/20/200		
/ILLAR, SILVIA	MIAMI, FL	2/20/200		
'ANES, REGLA	MIAMI, FL	2/20/200		
FELONY CONVICT	TION FOR HEALTH CARE FRAUD			
BLEGGI, NICOLA	LIVONIA, MI	2/20/200		
CARDENAS, KIMBERLY	,	2/20/200		
OTA, PETER		2/20/200		
DIAMOND-RILEY, ANGELA	CHICAGO, IL	2/20/200		
NGLER, KIMBERLY		2/20/200		
ERNANDEZ, JOSE		2/20/200		
IOPKINS, WYCONDA		2/20/200		
LEIN, REBECCA		2/20/200		
ADD, ELLA		2/20/200		
MANZE, PATRICK	CHATHAM, NJ	2/20/200		
MARTIN-FREDERICK, CHARMAINE		2/20/200		
MILLER, TONI	The state of the s	2/20/200		
DBEROI, TEJBIR		2/20/200		
DYSTER, CHERYL		2/20/200		
,	WESTMINSTER, SC			

Subject name	Address	Effective date
WINER, CLARENCE	KANSAS CITY, MO	2/20/2009
FELONY CONTRO	DL SUBSTANCE CONVICTION	
BAKER, MICHAEL	OCALA, FL	2/20/200
BERTUCCI, PAMELA	METAIRIE, LA	2/20/200
CARROLL, BRIDGET		2/20/200
HOPWOOD, BECKY		2/20/200
JACKSON, TERI	AVINGER, TX	2/20/200
JACOBS, TAMIE	WEST PALM BEACH, FL	2/20/200
MODI, KAILAS	, , , , , , , , , , , , , , , , , , ,	2/20/200
PEPPER, CHRISTI	CADIZ, KY	2/20/200
PORTALATIN, MICHELE	FLORISSANT, MO	2/20/200
PATIENT ABUS	E/NEGLECT CONVICTIONS	
BALL, SANDRA		2/20/200
BELLANTON, JUDITH	· ·	2/20/200
BYNEM, SHAKESHA	, = , = =	2/20/200
CRAWFORD, PHILIP		2/20/200
EVANS, BRIAN	, -	2/20/200
EVANS, THOMAS	, -	2/20/200
GONZALEZ, ERNESTO	,	2/20/200
GREENE, MARY		2/20/200
HUNTER, FRANK	· · · · · · · · · · · · · · · · · · ·	2/20/200
MANDOLESI, MICHAEL	, -	2/20/200
MCCRAY, RHONDANEACE, DARLENE	_ ,	2/20/2009 2/20/2009
OWENS. BUDDY	· ·	2/20/200
PADGETT, TAMEKIA	·	2/20/200
PAVIA, DAILLYN		2/20/200
SANDIFER, TERESA		2/20/200
SLAVNEY, KENNETH	· ·	2/20/2009
THOMAS, TAMIKA	· · · · · · · · · · · · · · · · · · ·	2/20/2009
WATTS, WARDELL	· ·	2/20/2005
LICENSE REVOCATION	DN/SUSPENSION/SURRENDERED	
ADAMS, JO	VIRGIE, KY	2/20/2009
ALBRITTON, CYNTHIA		2/20/2009
AMES, DIANNE		2/20/200
ARNOLD, LISA	WEST PALM BEACH, FL	2/20/200
ATENCIO, SALLY	HENDERSON, NV	2/20/200
ATWOOD-ALDEN, DONNA	NEWBURYPORT, MA	2/20/2009
AUTHELET, JERILYN	WARREN, RI	2/20/200
BAILEY, CHERYL	= ·	2/20/200
BAUKNIGHT, POLLA		2/20/200
BINGHAM, NATHANIEL	· · · · · · · · · · · · · · · · · · ·	2/20/200
BLANTON, EBONY	, -	2/20/200
BOUTROS, SAMIR		2/20/200
BOWLING, SARAH		2/20/200
CALLERAME, WILLIAM	,	2/20/200
CAMPBELL, CHRISTINE		2/20/200
CHANEY, CINDY	·	2/20/200
CHEATHAM, DOUGLAS	,	2/20/200
CORDELL KIMPERLY		2/20/200
CORDELL, KIMBERLYCOX. CASEY	_ ,	2/20/2009 2/20/2009
COX, CASEY	,	2/20/2009 2/20/2009
CRIST-LEGG, BARBARA	,	2/20/200
CRUZ. VANIDY	,	2/20/200
DELACRUZ BROWN, JENNIFER		2/20/200
DIAZ, MAGDALENA		2/20/200
DORAN, MICHAEL	1	2/20/200
EDDINGS, JOLENE	· · · · · · · · · · · · · · · · · · ·	2/20/200
FERNANDES, SHARON		2/20/200
FLANDERS, CHERYL	· ·	2/20/200
FORD, KAYLA		2/20/200
FREE, MICHAEL	· ·	2/20/200
FULLMAN, LINDA	7	2/20/200
	· · · · · · · · · · · · · · · · · · ·	2/20/200
FUQUA, LYNN		
FUQUA, LYNNGABALDON, JENNIFER		2/20/200
	FLAGSTAFF, AZ	2/20/200 2/20/200

GLOYD, JASON	COCKEYSVILLE, MD	2/20/2005 2/20/2005 2/20/2005 2/20/2005
GLUSCHKE, REGINA	POMPANO BEACH, FL	2/20/2005
GOMEZ, ALVERA	LAKE HAVASU, AZHOLYOKE, MAQUINCY, FL	
GREEN, KARMEN	HOLYOKE, MAQUINCY, FL	
	QUINCY, FL	2/20/2005
		2/20/2005
		2/20/2005
·	DENVER, CO	2/20/2005
	LAWRENCEBURG, KY	2/20/2005
	PORTER, TX	2/20/2005
	BASTROP, TXLOCKPORT, IL	2/20/2005 2/20/2005
	ALAMEDA, CA	2/20/2005
· · · · · · · · · · · · · · · · · · ·	CRESTWOOD, KY	2/20/2005
	TUSKEGEE, AL	2/20/2005
,	SODDY DAISY, TN	2/20/2005
	TEMECULA, CA	2/20/2005
	PORT ARTHUR, TX	2/20/2005
· ·	SUMMERVILLE, SC	2/20/2005 2/20/2005
,	HUNTSVILLE, AL	2/20/2005
	NICHOLASVILLE, KY	2/20/2005
KERR, SHEILA	OLIVE BRANCH, MS	2/20/2005
	OLALLA, WA	2/20/2005
·	HUNTSVILLE, AL	2/20/2005
	BAKERSFIELD, CAFT LAUDERDALE, FL	2/20/2005 2/20/2005
	LONG BRANCH, NJ	2/20/2005
	WYNNEWOOD, PA	2/20/2005
LOMAX, AVERY	ONTARIO, CA	2/20/2005
	ATLANTIC BEACH, FL	2/20/2005
	SPOKANE, WA	2/20/2005
	INDIANAPOLIS, INLITTLE ROCK, AR	2/20/2005 2/20/2005
	GLENDALE, AZ	2/20/2005
	MARRERO, LA	2/20/2005
	JACKSONVILLE, FL	2/20/2005
	EL PASO, TX	2/20/2005
	BERWYN, IL	2/20/2005
·	SPRING CITY, TN ORLANDO, FL	2/20/2005 2/20/2005
· · · · · · · · · · · · · · · · · · ·	BENSALEM, PA	2/20/2005
	PENSACOLA, FL	2/20/2005
	MESA, AZ	2/20/2005
	W WARWICK, RI	2/20/2005
	YOUNGTOWN, AZ WESTFIELD, NJ	2/20/2005 2/20/2005
*	CRESTVIEW, FL	2/20/2005
,	MOCKSVILLE, NC	2/20/2005
ROAN, RHONDA	MONROE, LA	2/20/2005
*	ROCKPORT, TX	2/20/2005
	TUCSON, AZ	2/20/2005
·	EL MIRAGE, AZARLINGTON, TX	2/20/2005 2/20/2005
	CUMBERLAND, KY	2/20/2005
· · · · · · · · · · · · · · · · · · ·	SPOKANE, WA	2/20/2005
SHEPHERD, LORETTA	ABERDEEN, OH	2/20/2005
SMITH, ANGELINE	ORLANDO, FL	2/20/2005
	POLO, IL	2/20/2005
SMITH MEON	SURPRISE, AZLANCASTER, CA	2/20/2005
	PHILADELPHIA, PA	2/20/2005 2/20/2005
	NICHOLASVILLE, KY	2/20/2005
	LAFAYETTE, IN	2/20/2005
TANNER, PATTI	BARLOW, KY	2/20/2005
	WARE, MA	2/20/2005
,	SUNLAND, CA	2/20/2005
	CLOVIS, CA	2/20/2005
	PORT ST LUCIE, FL	2/20/2005 2/20/2005
· ·	SUWANEE, GA	2/20/2005
	MAYSLICK, KY	2/20/2005
*	BUFFALO, NY	2/20/2005
WELBORN, VELVET	FULTON, MS	2/20/2005

Subject name	Address	Effective date
WETTEROW, MELANIE WHITE, SEAN WHITTENTON, ANGELA WILD, LISA WILLIAMS, PATRICIA WILLIAMS, WARREN WOOLLEY, TODD ZIBA, GRACE	PHOENIX, AZ	2/20/2005 2/20/2005 2/20/2005 2/20/2005 2/20/2005 2/20/2005 2/20/2005 2/20/2005
FRAUD/KICKBACKS/PROHIBITED AC	CTS/SETTLEMENT AGREEMENTS	
GLANZER, ELROY	IDAHO FALLS, ID	2/18/2004
OWNED/CONTROLLED BY	CONVICTED ENTITIES	
MONTECINO'S DRUGS, INC	MARRERO, LAEDEN VALLEY, MN	2/20/2005 2/20/2005
DEFAULT ON H	IEAL LOAN	
BUKOWSKI, TODD	WASHINGTON, DC	11/19/2004 2/20/2005 2/20/2005

Dated: February 1, 2005.

Katherine B. Petrowski,

Director, Exclusions Staff, Office of Inspector General.

[FR Doc. 05–2369 Filed 2–7–05; 8:45 am] BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Methods for Treating Active Uveitis

Robert Nussenblatt (NEI) and Thomas Waldmann (NCI), Zhuqing Li (NEI), Ronald Buggage (NEI).

U.S. Provisional Patent Application No. 60/616,760 filed 06 Oct 2004 (DHHS Reference No. E–328–2004/0–US–01). Licensing Contact: Susan Carson; 301/435–5020; carsonsu@mail.nih.gov.

Intraocular inflammatory disease (uveitis) is characterized by pain and a decrease in vision that can lead to blindness if not treated appropriately. The incidence and prevalence of the disease are approximately 52/100,000 and 112/100,000, and this translates into an incidence of 151,000 per year and a prevalence of 322,000. The numbers are expected to increase as the population ages. Treatment of severe uveitis often focuses on the control of the inflammatory symptoms using high dose corticosteroids, cytotoxic drugs or other immunosuppressive agents and there is a need for therapies that reduce the major side effects associated with the prolonged use of systemic steroids (e.g. hyperglycemia, osteoporosis and loss of immunocompetence).

Daclizumab is a humanized anti-Tac (HAT) antibody that specifically binds to the alpha subunit (CD25 or Tac subunit) of the human high affinity interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes. Dr. Nussenblatt and colleagues at the NEI have previously shown that daclizumab can be used to successfully treat quiescent uveitis. Long term daclizumab therapy at a dose of 1mg/kg can be used instead of standard immunosuppressive agents to treat severe uveitis for more than 4 years with no adverse effects attributable to the

medication, and subcutaneously administered daclizumab also appeared to be clinically effective. However, subjects with active uveitis were less likely under this regimen to have their disease controlled (J. Autoimmunity (2003) 21, 283–293).

The present invention targets patients with refractory, active uveitis and consists of a high dose intravenous induction therapy using daclizumab at two different doses and times followed by a longer term maintenance therapy. Positive therapeutic effects have been seen with this protocol in a small group of patients within 4-6 weeks after the initiation of therapy. As previous work indicated that IL-2R receptors have a slow turnover rate on CD4 positive subpopulation of lymphocytes, a possible mechanism of action of this new protocol is saturation of CD25 (TAC) receptors on cells in sequestered

Available for licensing are methods directed to this treatment of active uveitis using a high dose pulsatile induction protocol of an interleukin-2 (Il-2) receptor antagonist. Methods are also provided for the treatment of corneal transplant rejection, limbal stem cell rejection following transplantation, optic neuritis and dry eye.

Novel Thermostable Y-Family DNA Polymerases

Roger Woodgate (NICHD), John P. McDonald (NICHD), and Wei Yang (NIDDK).

U.S. Provisional Patent Application No. 60/573,684 filed 20 May 2004 (DHHS Ref No. E–166–2004/0–US–01); U.S. Provisional Patent Application No. 60/623, 490 filed 29 Oct 2004 (DHHS Ref No. E–166–2004/1–US–01).